levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


«12...1617181920212223242526...9091»
  • ||||||||||  Journal:  An Outbreak of Vancomycin-Resistant Enterococci in a City Hospital Intensive Care Unit: Molecular Characterization of Resistance. (Pubmed Central) -  Dec 27, 2023   
    In our study, in the clonal association analysis performed by isolating VREfm in rectal swab samples, it was found that 88.8% of the samples were indistinguishably similar, and that the increase in the number of VREfm infections after the index case in our hospital was associated with the epidemic. VREfm infections cause long-term hospitalization, costs and also deaths, which shows the seriousness of the event, and the importance of the combination of epidemiological and molecular analysis in epidemic research.
  • ||||||||||  levofloxacin / Generic mfg., clarithromycin / Generic mfg.
    Journal:  Eradicate Helicobacter pylori first, or treat peptic ulcer disease? (Pubmed Central) -  Dec 25, 2023   
    The sequence of H. pylori eradication and peptic ulcer disease treatment does not significantly affect the primary outcomes. Patient gender and the choice of antibiotic combination are important factors in H. pylori eradication, whereas peptic ulcer disease type plays a key role in ulcer healing.
  • ||||||||||  Journal:  Regional and National Trends in Consumption of Antimicrobials in Pakistan; Pre and Post-COVID (2019-2021). (Pubmed Central) -  Dec 24, 2023   
    Therefore, reviewing and strict implementation of the antimicrobial policies including 'rational use of antibiotics' is recommended. Although the increase in consumption of all antibiotics is concerning, the steep increase in the use of watch and reserve category antibiotics during the study period calls for immediate actions to limit and regulate their usage.
  • ||||||||||  cefepime hydrochloride / Generic mfg., levofloxacin / Generic mfg., meropenem / Generic mfg.
    Review, Journal:  Pseudomonas otitidis bacteremia in an immunocompromised patient with cellulitis: case report and literature review. (Pubmed Central) -  Dec 23, 2023   
    However, its biochemical properties are similar to those of Pseudomonas aeruginosa; therefore, its accurate identification is critical. In the present study, we rapidly identified P. otitidis using MALDI-TOF MS and switched from carbapenems to an appropriate antimicrobial therapy, resulting in a successful outcome.
  • ||||||||||  levofloxacin / Generic mfg., amikacin sulfate / Generic mfg.
    Journal:  Lysozyme binding with amikacin and levofloxacin studied by tritium probe, fluorescence spectroscopy and molecular docking. (Pubmed Central) -  Dec 22, 2023   
    In the case of levofloxacin, the formation of lysozyme-ligand complex in aqueous solution is possible without changing the microenvironment of the active center of the protein. Binding of levofloxacin to the active center of the enzyme was the most favorable, but Asp52 and Glu35 that are responsible for the enzymatic activity of lysozyme, were not affected.
  • ||||||||||  levofloxacin / Generic mfg., fosfomycin tromethamine / Generic mfg.
    Trial completion date, Trial primary completion date:  Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention (clinicaltrials.gov) -  Dec 20, 2023   
    P1/2,  N=100, Recruiting, 
    Binding of levofloxacin to the active center of the enzyme was the most favorable, but Asp52 and Glu35 that are responsible for the enzymatic activity of lysozyme, were not affected. Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024
  • ||||||||||  Cytovene (ganciclovir) / Roche
    It's not always IBD (Sancy - Hilton Antwerp Old Town) -  Dec 19, 2023 - Abstract #BWG2024BWG_76;    
    The patient was put on ganciclovir and broad-spectrum antibiotics based on cephalosporines (ceftriaxone) and quinolones (levofloxacin), and immunoglobulin (tegelin). She passed away within 24 hours following a state of septic shock.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  In situ sonochemical synthesis of flower-like N-graphyne/BiOClBr microspheres for efficient removal of levofloxacin. (Pubmed Central) -  Dec 18, 2023   
    The improved photocatalytic activity is attributed to the enhanced visible light response and the accelerated transfer/separation of photogenerated carriers by N-graphyne, which are verified using UV-vis absorption spectra, photocurrents, photopotentials, Nyquist plots, and Mott-Schottky curves. This study develops a new perspective for the synthesis and modification of BiOX solid solution, which can be used as an efficient photocatalyst.
  • ||||||||||  ceftriaxone / Generic mfg., levofloxacin / Generic mfg.
    Journal:  A case of Elizabethkingia meningoseptica septicemia. (Pubmed Central) -  Dec 18, 2023   
    After 11 days of anti-infection treatment, the patient was discharged with negative blood culture,and his hypersensitive C-reactive protein and neutrophile granulocyte declined. The patient received levofloxacin tablets for anti-infection treatment for 14 d after discharge, and no signs of infection were observed in three months' following up.
  • ||||||||||  Trial primary completion date:  Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection (clinicaltrials.gov) -  Dec 15, 2023   
    P=N/A,  N=500, Recruiting, 
    Using a prior culture as a guide can enhance the probability of selecting an effective empirical agent. Trial primary completion date: Oct 2023 --> Feb 2024
  • ||||||||||  Hodgkin (Ninth Avenue & Dolores St.) -  Dec 13, 2023 - Abstract #WRMC2024WRMC_239;    
    Patient is scheduled to begin chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine for atleast 2 cycles. Hodgkin
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  COPAT: Comparing Oral Versus Parenteral Antimicrobial Therapy (clinicaltrials.gov) -  Dec 11, 2023   
    P4,  N=135, Enrolling by invitation, 
    Hodgkin Not yet recruiting --> Enrolling by invitation | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
  • ||||||||||  Characterization of Infectious Complications during the Expected Duration of Cytokine Release Syndrome (CRS) in Patients Receiving CAR T Cell Therapy  () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_905;    
    We retrospectively reviewed 191 patients treated with autologous CAR T cell products (idecabtagene vicleucel, ciltacabtagene autoleucel, tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel) at Mount Sinai Hospital from April 2017 until February 2023...Levofloxacin as prophylaxis was given to 35% (60/170). These results suggest that judicious use of broad-spectrum antibiotics and limited infectious workup may be considered in clinically stable and non-neutropenic patients with CRS occurring during the pre-specified period post CAR T cell infusion.
  • ||||||||||  levofloxacin / Generic mfg.
    Review, Journal:  Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: Exploring pros and cons. (Pubmed Central) -  Dec 11, 2023   
    The debate surrounding fluoroquinolone prophylaxis calls for individualized risk assessment based on patient characteristics and local AMR patterns, and prophylaxis should be restricted to patients at the highest risk of serious infection during the highest risk periods to ensure that the risk-benefit analysis is in favor of individual and community benefit. More research is needed to address important unanswered questions about fluoroquinolone prophylaxis in neutropenic patients with cancer or receiving HSCT.
  • ||||||||||  Journal:  Comparative Study on the Efficacy of Two Perioperative Chemotherapy Regimens for Lumbar Brucellosis. (Pubmed Central) -  Dec 8, 2023   
    Both groups did not experience significantly different perioperative and postoperative adverse reactions (P>0.05). For lumbar brucellosis spondylitis with neurological injury, quadruple perioperative chemotherapy of rifampicin, doxycycline, levofloxacin and ceftriaxone can significantly reduce perioperative inflammation, and improve low back/leg pain, as well as promoting neurological function recovery in the short term.
  • ||||||||||  levofloxacin / Generic mfg., rifampicin / Generic mfg., moxifloxacin intravenous / Generic mfg.
    Journal:  Protein binding investigation of first-line and second-line antituberculosis drugs. (Pubmed Central) -  Dec 4, 2023   
    The free concentration predicted by mathematical model was suitable for levofloxacin and linezolid, unlike for rifampicin, where the real free concentration should be measured. Further investigations should be carried out to investigate the benefit of the free concentration for levofloxacin, linezolid and rifampicin mainly in the critical period of active tuberculosis associated to hypoalbuminemia.
  • ||||||||||  levofloxacin / Generic mfg., amikacin sulfate / Generic mfg., moxifloxacin intravenous / Generic mfg.
    Journal:  Distribution of multi-drug resistant tuberculosis in Ekiti and Ondo states, Nigeria. (Pubmed Central) -  Dec 4, 2023   
    VacAs1m2 strains were more prone to metronidazole resistance than vacAs1m1 strains. All the Rifampicin-resistant TB strains were susceptible to the aminoglycosides (Amikacin, Capreomycin and Kanamycin), also with high susceptibility to the fluoroquinilones: Moxifloxacin (100
  • ||||||||||  Trial completion date, Trial primary completion date:  Early Antibiotics After Aspiration in ICU Patients (clinicaltrials.gov) -  Nov 30, 2023   
    P4,  N=100, Recruiting, 
    Overall, hygiene, prompt treatment, and standard protocol should be utilized to treat those infected and minimize the spread. Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024